![Simon Dew](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Simon Dew
Corporate Officer/Principal chez Royal Pharmaceutical Society of Great Britain
Profil
Simon Dew is currently a Member at the Royal Pharmaceutical Society of Great Britain.
Previously, he held positions as Vice President-Business & Corporate Development at Mereo BioPharma Group Plc, Vice President-Business Development at Evox Therapeutics Ltd., Vice President-Corporate Strategy at Gyroscope Therapeutics Ltd., VP-Corporate Strategy & Business Development at Astellas Pharmaceuticals AG, and Chief Business Officer at ReNeuron Group Plc.
Postes actifs de Simon Dew
Sociétés | Poste | Début |
---|---|---|
Royal Pharmaceutical Society of Great Britain
![]() Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - |
Anciens postes connus de Simon Dew
Sociétés | Poste | Fin |
---|---|---|
MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | - |
Evox Therapeutics Ltd.
![]() Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Gyroscope Therapeutics Ltd.
![]() Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Corporate Officer/Principal | - |
Astellas Pharmaceuticals AG | Corporate Officer/Principal | - |
RENEURON GROUP PLC | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
RENEURON GROUP PLC | Health Technology |
MEREO BIOPHARMA GROUP PLC | Health Technology |
Entreprise privées | 4 |
---|---|
Royal Pharmaceutical Society of Great Britain
![]() Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
Gyroscope Therapeutics Ltd.
![]() Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Astellas Pharmaceuticals AG | |
Evox Therapeutics Ltd.
![]() Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |